HTG Molecular Diagnostics, Inc.
シンボルマーク: HTGM
NASDAQ
0.48
USD今日の市場価格
-0.0745
PER(株価収益率
-0.0008
PEGレシオ
1.06M
MRK キャップ
- 0.00%
DIV利回り
HTG Molecular Diagnostics, Inc. (HTGM) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 39.4 | 12.2 | 21.9 | 28.7 | |||||||||||
balance-sheet.row.short-term-investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.net-receivables | 4.77 | 1.4 | 2.1 | 1.6 | |||||||||||
balance-sheet.row.inventory | 5.21 | 0.9 | 2 | 1.5 | |||||||||||
balance-sheet.row.other-current-assets | 4.89 | 1.1 | 1.2 | 1.1 | |||||||||||
balance-sheet.row.total-current-assets | 54.94 | 15.7 | 27.2 | 32.9 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 6.65 | 1.6 | 2.5 | 2.2 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 2.88 | 0.5 | 0.8 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 9.52 | 2.1 | 3.3 | 2.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.account-payables | 4.08 | 1.2 | 1.6 | 1.3 | |||||||||||
balance-sheet.row.short-term-debt | 19.02 | 4.3 | 5.6 | 3.7 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 4.92 | 0.5 | 6.1 | 8.9 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 8.71 | 2.8 | 2.6 | 2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 20.01 | 4.1 | 10.1 | 13.5 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 3.41 | 1 | 1.4 | 1.1 | |||||||||||
balance-sheet.row.total-liab | 51.81 | 12.4 | 20.1 | 20.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -910.86 | -229.9 | -208.3 | -191.2 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.02 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 923.5 | 235.3 | 218.7 | 205.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 64.46 | - | - | - | |||||||||||
Total Investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.total-debt | 23.94 | 4.8 | 11.7 | 12.6 | |||||||||||
balance-sheet.row.net-debt | -0.24 | -7.4 | 2.1 | -9.8 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.49 | 0.6 | 0.7 | 1.3 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -1.4 | 0.7 | |||||||||||
cash-flows.row.stock-based-compensation | 0.68 | 0.8 | 1.4 | 1.8 | |||||||||||
cash-flows.row.change-in-working-capital | -0.16 | -0.1 | -1 | -0.2 | |||||||||||
cash-flows.row.account-receivables | -0.38 | 0.7 | -0.8 | 1.6 | |||||||||||
cash-flows.row.inventory | 0.27 | 0.1 | -1.4 | -0.3 | |||||||||||
cash-flows.row.account-payables | -0.2 | -0.5 | 0.5 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0.16 | -0.4 | 0.7 | -1.5 | |||||||||||
cash-flows.row.other-non-cash-items | 2.31 | 1.9 | 0.9 | 0.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -16.83 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.acquisitions-net | -99828.51 | 0 | -25018 | -72.5 | |||||||||||
cash-flows.row.purchases-of-investments | -11.15 | -7.6 | -18.6 | -12.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 14.52 | 19.9 | 12.6 | 31.6 | |||||||||||
cash-flows.row.other-investing-activites | 99828.64 | 0.1 | 25018 | 72.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 3.48 | 12.4 | -6.7 | 18.7 | |||||||||||
cash-flows.row.debt-repayment | -7.16 | -7.8 | -0.8 | -3.6 | |||||||||||
cash-flows.row.common-stock-issued | 2.8 | 1.4 | 10.7 | 7.5 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 6.09 | 15 | 0.5 | 5.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1.73 | 8.6 | 10.4 | 9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -11.62 | 2.6 | -12.8 | 11.5 | |||||||||||
cash-flows.row.cash-at-end-of-period | 24.18 | 12.2 | 9.6 | 22.4 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 35.79 | 9.6 | 22.4 | 10.9 | |||||||||||
cash-flows.row.operating-cash-flow | -16.83 | -18.4 | -16.5 | -16.3 | |||||||||||
cash-flows.row.capital-expenditure | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.free-cash-flow | -16.85 | -18.4 | -17.2 | -16.7 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6.21 | 6.4 | 8.9 | 8.5 | |||||||||||
income-statement-row.row.cost-of-revenue | 4.87 | 4.6 | 4.1 | 4 | |||||||||||
income-statement-row.row.gross-profit | 1.35 | 1.8 | 4.8 | 4.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 6.47 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 20.94 | 22.6 | 22.6 | 24.1 | |||||||||||
income-statement-row.row.cost-and-expenses | 25.8 | 27.2 | 26.7 | 28.1 | |||||||||||
income-statement-row.row.interest-income | 0.19 | 0.1 | 0 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.55 | 0.7 | -1.7 | 1.6 | |||||||||||
income-statement-row.row.ebitda-caps | -19.29 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -19.59 | -20.8 | -17.8 | -19.6 | |||||||||||
income-statement-row.row.income-before-tax | -20.14 | -21.6 | -17.1 | -20.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0.01 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 |
よくある質問
HTG Molecular Diagnostics, Inc.HTGM 総資産とは何ですか?
HTG Molecular Diagnostics, Inc. (HTGM) 総資産は 17777655.000.
企業の年間売上高とは?
年間収益は 3471815.000である.
企業の利益率は?
利益率は 0.184 である.
企業のフリーキャッシュフローとは?
フリーキャッシュフローは -4.967.
企業の純利益率は?
純利益率は -3.020 である.
企業の総収入は?
総収入は -2.946 である.
HTG Molecular Diagnostics, Inc. (HTGM) 純利益(純利益)とは何ですか?
純利益(純利益)は -21594476.000.
負債総額は?
負債合計は 4833948.000 である.
営業費用はいくらですか?
営業費用は 22623682.000 である.
会社の現金はいくらですか?
企業の現金は 2996409.000 である.